
Raza Malik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9279460/publications.pdf Version: 2024-02-01



Ρασα Μαιικ

#	Article	IF	CITATIONS
1	Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. Liver Transplantation, 2018, 24, 380-393.	2.4	101
2	The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 564-568.	2.8	80
3	Validation of Hepascore, Compared With Simple Indices of Fibrosis, in Patients With Chronic Hepatitis C Virus Infection in United States. Clinical Gastroenterology and Hepatology, 2009, 7, 696-701.	4.4	72
4	Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1562-1568.	2.8	44
5	Stiffness and Impedance: The New Liver Biomarkers. Clinical Gastroenterology and Hepatology, 2007, 5, 1144-1146.	4.4	20
6	Primary Stent Placement for Hepatic Artery Stenosis After Liver Transplantation: Improving Primary Patency and Reintervention Rates. Liver Transplantation, 2018, 24, 1377-1383.	2.4	19
7	Identifying Barriers to the Treatment of Chronic Hepatitis C Infection. Digestive Diseases, 2020, 38, 46-52.	1.9	16
8	Efficacy of TIPS Reduction for Refractory Hepatic Encephalopathy, Right Heart Failure, and Liver Dysfunction. American Journal of Roentgenology, 2021, 216, 1267-1272.	2.2	15
9	Chronic hepatitis C infection — Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Digestive and Liver Disease, 2019, 51, 183-189.	0.9	11
10	The Role of Liver Fibrosis Assessment in the Management of Patients with Chronic Hepatitis B Infection: Lessons Learned from a Single Centre Experience. Hepatitis Research and Treatment, 2011, 2011, 1-5.	2.0	2
11	Serum fibrosis markers to predict clinical and histological progression in hepatitis C non-responders.	12.1	1